Literature DB >> 18445095

Characteristics of symptomatic reflux episodes on Acid suppressive therapy.

Radu Tutuian1, Marcelo F Vela, Elizabeth G Hill, Inder Mainie, Amit Agrawal, Donald O Castell.   

Abstract

BACKGROUND: Persistent symptoms on acid suppressive therapy are due to either acid or nonacid gastroesophageal reflux (GER) episodes or are not related to reflux. AIM: To compare physical and chemical characteristics of GER episodes associated with symptoms in patients on acid suppressive therapy.
METHODS: Patients with persistent symptoms on acid suppressive therapy underwent combined impedance-pH monitoring. Reflux episodes were classified as acid if nadir pH was <4.0, and nonacid if it remained at >/=4.0, separated into liquid-only or mixed (liquid-gas), and considered to reach the proximal esophagus if liquid was present 15 cm above the lower esophageal sphincter (LES). Reflux episodes were considered symptomatic if patients recorded a symptom within 5 min after the reflux episode. Risk factors of symptomatic reflux episodes were identified using multivariable generalized estimating equations (GEEs).
RESULTS: One hundred twenty patients (85 women, median age 54 yr, range 18-85 yr) recorded 3,547 reflux episodes (84.3% nonacid, 50.6% mixed), of which 468 (13.2%) were symptomatic. Based on multivariable GEE analysis with episode-level symptom status (symptomatic vs nonsymptomatic) as the outcome variable, reflux episode acidity was not significantly associated with symptoms (P= 0.40). Mixed reflux episodes were significantly associated with symptoms relative to liquid-only episodes (odds ratio [OR] 1.49, 95% confidence interval [CI] 1.19-1.87, P= 0.0005), as were reflux episodes reaching the proximal esophagus compared with those reaching the distal esophagus only (OR 1.28, 95% CI 1.06-1.55, P= 0.012).
CONCLUSION: The majority of reflux episodes on acid suppressive therapy are asymptomatic. Reflux episodes extending proximally and having a mixed (liquid-gas) composition are significantly associated with symptoms, irrespective of whether pH is acid (<4) or nonacid (>/=4).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18445095     DOI: 10.1111/j.1572-0241.2008.01791.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  35 in total

1.  Treatment of Refractory Gastroesophageal Reflux Disease.

Authors:  Rishi D Naik; Matthew H Meyers; Michael F Vaezi
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-04

Review 2.  Overlap Between GERD and Functional Esophageal Disorders-a Pivotal Mechanism for Treatment Failure.

Authors:  Ofer Z Fass; Ronnie Fass
Journal:  Curr Treat Options Gastroenterol       Date:  2019-03

3.  Airway reflux, cough and respiratory disease.

Authors:  Ian D Molyneux; Alyn H Morice
Journal:  Ther Adv Chronic Dis       Date:  2011-07       Impact factor: 5.091

Review 4.  Management of refractory typical GERD symptoms.

Authors:  Emidio Scarpellini; Daphne Ang; Ans Pauwels; Adriano De Santis; Tim Vanuytsel; Jan Tack
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-04-14       Impact factor: 46.802

Review 5.  Antireflux surgery for dysplastic Barrett.

Authors:  Marco E Allaix; Marco G Patti
Journal:  World J Surg       Date:  2015-03       Impact factor: 3.352

Review 6.  NERD: an umbrella term including heterogeneous subpopulations.

Authors:  Edoardo Savarino; Patrizia Zentilin; Vincenzo Savarino
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-26       Impact factor: 46.802

7.  The role of weakly acidic reflux in proton pump inhibitor failure, has dust settled?

Authors:  Emmanouela Tsoukali; Daniel Sifrim
Journal:  J Neurogastroenterol Motil       Date:  2010-07-27       Impact factor: 4.924

8.  Alginate controls heartburn in patients with erosive and nonerosive reflux disease.

Authors:  Edoardo Savarino; Nicola de Bortoli; Patrizia Zentilin; Irene Martinucci; Luca Bruzzone; Manuele Furnari; Santino Marchi; Vincenzo Savarino
Journal:  World J Gastroenterol       Date:  2012-08-28       Impact factor: 5.742

9.  Prevention of DNA damage in Barrett's esophageal cells exposed to acidic bile salts.

Authors:  Vikas Bhardwaj; Andela Horvat; Olga Korolkova; Mary K Washington; Wael El-Rifai; Sergey I Dikalov; Alexander I Zaika
Journal:  Carcinogenesis       Date:  2016-09-21       Impact factor: 4.944

10.  Majority of symptoms in esophageal reflux PPI non-responders are not related to reflux.

Authors:  S Roman; L Keefer; H Imam; P Korrapati; B Mogni; K Eident; L Friesen; P J Kahrilas; Z Martinovich; J E Pandolfino
Journal:  Neurogastroenterol Motil       Date:  2015-09-04       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.